Single agent ZD-1839 [gefitinib] in patients with advanced head and neck carcinoma or non-small cell lung cancer aged 75 years and older (and in a cohort of patients 50 years old and younger).

Trial Profile

Single agent ZD-1839 [gefitinib] in patients with advanced head and neck carcinoma or non-small cell lung cancer aged 75 years and older (and in a cohort of patients 50 years old and younger).

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2013

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Head and neck cancer; Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 11 Jan 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 16 Jun 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 14 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top